Nightingale Health Plc, a Finnish healthtech company with a focus on preventive care, is acquiring Negen, another Finnish healthtech company that is especially focused on genetic testing.
Nightingale was founded in 2013 as a health technology company. The company aims to keep people healthy rather than just treat illnesses. Nigthingale’s areas of focus are biotechnology, blood analysis, medical diagnostics, metabolic profiling and many more. The company currently offers a blood test that measures over 200 metabolites from a single blood sample and detects many health risks.
Now Nightingale is combining proprietary blood test with genomics by acquiring Negen. This combination can provide new possibilities in the realm of early disease risk detection and accelerate preventative medicine. The first products that integrate these two distinct technologies are expected to be launched in the second half of 2022.
Nightingale’s expansion to genomics
Negen is a Helsinki-based genetic testing and analysis technology company that was founded in 2015. The company offers genetic tests that are designed to show genetic risks for certain diseases and health problems such as type 2 diabetes and coronary heart disease. Negen is in the early stages of commercialisation and with this acquisition Nightingale will purchase all shares of Negen.
About the acquisition of Negen by Nigthingale and the integration of two different technologies, Teemu Suna, the founder and CEO of Nightingale, has stated that while there are companies offering these tests separately, they are combining the two in a way that was never done before. This way, he said, they will be able to do better preventative health analysis. Then he went on to add:
“We capture the lifestyle factors with our proprietary blood test more holistically than other blood tests and we can rapidly match other consumer genetic testing companies through the Negen acquisition and our own excellence centre. No other company in the world can match this combination.”